In vivo effects of mesenchymal stromal cells in two patients with severe acute respiratory distress syndrome

Stem Cells Translational Medicine

Volumn 4, Issue 10, 2015, Pages 1199-1213

  Simonson, Oscar E ^a   Mougiakakos, Dimitrios ^b   Heldring, Nina ^a   Bassi, Giulio ^c   Johansson, Henrik J ^d   Dalén, Magnus ^a   Jitschin, Regina ^a   Rodin, Sergey ^d   Corbascio, Matthias ^a,e   El Andaloussi, Samir ^a   Wiklander, Oscar P B ^a   Nordin, Joel Z ^a   Skog, Johan ^f   Romain, Charlotte ^f   Koestler, Tina ^f   Hellgren Johansson, Laila ^g   Schiller, Petter ^g   Joachimsson, Per Olof ^g   Hägglund, Hans ^g   Mattiasmattsson, Mattias ^g   Lehtiö, Janne ^d   Faridani, Omid R ^h   Sandberg, Rickard ^d,h   Korsgren, Olle ^g   Krampera, Mauro ^c   Weiss, Daniel J ⁱ   Grinnemo, Karl Henrik ^a,e   Le Blanc, Katarina ^a   more..

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF VERONA   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

^e Vaccine and Gene Therapy Institute   (United States)

^f Exosome Diagnostics Inc   (United States)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

ⁱ UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Acute respiratory distress syndrome; Bone marrow stromal cells; Cell transplantation; Cellular therapy; Clinical translation; Pulmonary diseases; Respiratory tract; Stem cells

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; PROTEOME;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY LEAK SYNDROME; CASE REPORT; CELL THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG ALVEOLUS; MALE; MASS SPECTROMETRY; MESENCHYMAL STROMA CELL; MIDDLE AGED; MIXED LYMPHOCYTE REACTION; MONOCYTE; NEUTROPHIL; POLYMORPHONUCLEAR CELL; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; T LYMPHOCYTE; ALLOGRAFT; BLOOD; BONE MARROW CELL; CELL CULTURE; CENTRAL VENOUS CATHETERIZATION; CHEMISTRY; COMPASSIONATE USE; COMPLICATION; EPITHELIUM; EXOSOME; EXTRACORPOREAL OXYGENATION; HISTOCOMPATIBILITY; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; LIVING DONOR; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MIXED LYMPHOCYTE CULTURE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; SALVAGE THERAPY; SEVERE ACUTE RESPIRATORY SYNDROME;

ADULT; ALLOGRAFTS; CATHETERIZATION, CENTRAL VENOUS; CELLS, CULTURED; COMBINED MODALITY THERAPY; COMPASSIONATE USE TRIALS; EPITHELIUM; EXTRACELLULAR VESICLES; EXTRACORPOREAL MEMBRANE OXYGENATION; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; LUNG; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICRORNAS; MIDDLE AGED; MYELOID CELLS; PROTEOME; SALVAGE THERAPY; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84939823410     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0021     Document Type: Article

References (75)

1. Rincon F, Ghosh S, Dey S et al. Impact of acute lung injury and acute respiratory distress syndrome after traumatic brain injury in the United States. Neurosurgery 2012;71:795-803.
2. Angus DC, Clermont G, Linde-Zwirble WT et al. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: A phase III trial of inhaled nitric oxide. Crit Care Med 2006;34:2883-2890.
3. Walkey AJ, Summer R, Ho V et al. Acute respiratory distress syndrome: epidemiology and management approaches. Clin Epidemiol 2012; 4:159-169.
4. Zampieri FG, Mendes PV, Ranzani OT et al. Extracorporeal membrane oxygenation for severe respiratory failure in adult patients: A systematic review and meta-analysis of current evidence. J Crit Care 2013;28:998-1005.
5. Wilson JG, Matthay MA. Mechanical ventilation in acute hypoxemic respiratory failure: A review of new strategies for the practicing hospitalist. J Hosp Med 2014;9:469-475.
6. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308.
7. Lee JW, Zhu Y, Matthay MA. Cell-based therapy for acute lung injury: Are we there yet? Anesthesiology 2012;116:1189-1191.
8. Weiss DJ. Concise review: Current status of stem cells and regenerative medicine in lung biology and diseases. STEM CELLS 2014; 32:16-25.
9. Toonkel RL, Hare JM, Matthay MA et al. Mesenchymal stem cells and idiopathic pulmonary fibrosis: Potential for clinical testing. Am J Respir Crit Care Med 2013;188:133-140.
10. Lee JW, Fang X, Gupta N et al. Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung. Proc Natl Acad Sci USA 2009;106:16357-16362.
11. Curley GF, Ansari B, Hayes M et al. Effects of intratracheal mesenchymal stromal cell therapy during recovery and resolution after ventilator-induced lung injury. Anesthesiology 2013;118:924-932.
12. Mei SH, McCarter SD, Deng Y et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007;4:e269.
13. Xu J, Qu J, Cao L et al. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. J Pathol 2008;214:472-481.
14. Iyer SS, Torres-Gonzalez E, Neujahr DC et al. Effect of bone marrow-derived mesenchymal stem cells on endotoxin-induced oxidation of plasma cysteine and glutathione in mice. Stem Cells Int 2010;2010:868076.
15. Danchuk S, Ylostalo JH, Hossain F et al. Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-ainduced protein 6. Stem Cell Res Ther 2011; 2:27.
16. Mei SH, Haitsma JJ, Dos Santos CC et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010;182:1047-1057.
17. Gupta N, Su X, Popov B et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179:1855-1863.
18. Vallabhaneni KC, Haller H, Dumler I. Vascular smooth muscle cells initiate proliferation of mesenchymal stem cells by mitochondrial transfer via tunneling nanotubes. Stem Cells Dev 2012;21:3104-3113.
19. Kordelas L, Rebmann V, Ludwig AK et al. MSC-derived exosomes: A novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 2014;28:970-973.
20. Lai RC, Arslan F, Lee MM et al. Exosome secreted by MSC reduces myocardial ischemia/ reperfusion injury. Stem Cell Res (Amst) 2010;4: 214-222.
21. Zhang Y, Xie RL, Gordon J et al. Control of mesenchymal lineage progression by micro-RNAs targeting skeletal gene regulators Trps1 and Runx2. J Biol Chem 2012;287:21926-21935.
22. von Bahr L, Sundberg B, Lonnies L et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012;18:557-564.
23. Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (Safe Cell): A systematic review and meta-analysis of clinical trials. PLoS One 2012; 7:e47559.
24. Weiss DJ, Casaburi R, Flannery R et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013;143: 1590-1598.
25. Wilson JG, Liu KD, Zhuo H et al. Mesenchymal stem (stromal) cells for treatment of ARDS: A phase 1 clinical trial. Lancet Respir Med 2015;3:24-32.
26. Bianco P, Cao X, Frenette PS et al. The meaning, the sense and the significance: Translating the science of mesenchymal stem cells into medicine. Nat Med 2013;19:35-42.
27. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
28. Schaefer A, Jung M, Miller K et al. Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med 2010;42:749-758.
29. Mougiakakos D, Jitschin R, Johansson CC et al. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011;117:4826-4835.
30. Cassatella MA, Mosna F, Micheletti A et al. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. STEM CELLS 2011;29:1001-1011.
31. Dragovic RA, Gardiner C, Brooks AS et al. Sizing and phenotyping of cellular vesicles using nanoparticle tracking analysis. Nanomedicine (Lond) 2011;7:780-788.
32. Mi H, Muruganujan A, Thomas PD. PANTHER in 2013: Modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 2013; 41:D377-D386.
33. Ranieri VM, Rubenfeld GD, Thompson BT et al. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307:2526-2533.
34. Luft T, Conzelmann M, Benner A et al. Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease. Blood 2007; 110:4535-4542.
35. Collino F, Deregibus MC, Bruno S et al. Microvesicles derived from adult human bone marrow and tissue specific mesenchymal stem cells shuttle selected pattern of miRNAs. PLoS One 2010;5:e11803.
36. Krampera M. Mesenchymal stromal cell "licensing": A multistep process. Leukemia 2011;25:1408-1414.
37. Francois M, Romieu-Mourez R, Li M et al. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012;20:187-195.
38. Pelletier M, Micheletti A, Cassatella MA. Modulation of human neutrophil survival and antigen expression by activated CD4+ and CD8 + T cells. J Leukoc Biol 2010;88:1163-1170.
39. Mougiakakos D, Jitschin R, von Bahr L etal. Immunosuppressive CD14+HLA-DRlow/neg IDO + myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. Leukemia 2013;27:377-388.
40. Lança T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy. Onco Immunology 2012;1:717-725.
41. Pillay J, Kamp VM, van Hoffen E et al. A subset of neutrophils inhumansystemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012;122:327-336.
42. Poe SL, Arora M, Oriss TB et al. STAT1-regulated lung MDSC-like cells produce IL-10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. Mucosal Immunol 2013;6:189-199.
43. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013;13:392-402.
44. Chen HW, Chen HY, Wang LT et al. Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol 2013;190:5065-5077.
45. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: A jack of all trades, master of regulation. Nat Immunol 2008;9:239-244.
46. Jitschin R, Mougiakakos D, Von Bahr L et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem cell transplantation. STEM CELLS 2013;31:1715-1725.
47. Pietropaoli A, Georas SN. Resolving lung injury: A new role for Tregs in controlling the innate immune response. J Clin Invest 2009;119: 2891-2894.
48. El Andaloussi S, Mäger I, Breakefield XO et al. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013;12:347-357.
49. Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J Mol Sci 2014;15:4142-4157.
50. Zhu YG, Feng XM, Abbott J et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. STEM CELLS 2014;32: 116-125.
51. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006;7:131-142.
52. Blake JA, Dolan M, Drabkin H et al. Gene Ontology annotations and resources. Nucleic Acids Res 2013;41:D530-D535.
53. Matthay MA. Human mesenchymal stem cells for acute respiratory distress syndrome (START) NCT01775774. Bethesda, MD: U.S. National Library of Medicine, 2013. Available at https://clinicaltrials.gov/ct2/show/ NCT01775774.
54. Matthay MA. Human mesenchymal stem cells for acute respiratory distress syndrome (START), NCT0209764. Bethesda, MD: U.S. National Library of Medicine, 2014. Available at https://clinicaltrials.gov/ct2/show/ NCT02097641.
55. Gupta N, Krasnodembskaya A, Kapetanaki M et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533-539.
56. Krasnodembskaya A, Song Y, Fang X et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. STEM CELLS 2010;28:2229-2238.
57. Krasnodembskaya A, Samarani G, Song Y et al. Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. Am J Physiol Lung Cell Mol Physiol 2012;302:L1003-L1013.
58. Moll G, Jitschin R, von Bahr L et al. Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. PLoS One 2011;6:e21703.
59. Moll G, Rasmusson-Duprez I, von Bahr L et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? STEM CELLS 2012;30:1565-1574.
60. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. STEM CELLS 2012;30:1575-1578.
61. Mougiakakos D, Machaczka M, Jitschin R et al. Treatment of familial hemophagocytic lymphohistiocytosis with third-party mesenchymal stromal cells. Stem Cells Dev 2012;21: 3147-3151.
62. Sun J, Han ZB, Liao W et al. Intrapulmonary delivery of human umbilical cord mesenchymal stem cells attenuates acute lung injury by expanding CD4+CD25+ Forkhead Boxp3 (FOXP3)+ regulatory T cells and balancing antiand pro-inflammatory factors. Cell Physiol Biochem 2011;27:587-596.
63. Levy BD, Serhan CN. Resolution of acute inflammation in the lung. Annu Rev Physiol 2014;76:467-492.
64. Krampera M, Galipeau J, Shi Y et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013;15:1054-1061.
65. Bustos ML, Huleihel L, Meyer EM et al. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. STEM CELLS TRANSLATIONAL MEDICINE 2013;2: 884-895.
66. Kim HS, Choi DY, Yun SJ et al. Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res 2012; 11:839-849.
67. Fiedler J, Etzel N, Brenner RE. To go or not to go: Migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. J Cell Biochem 2004;93:990-998.
68. Ball SG, Shuttleworth CA, Kielty CM. Vascular endothelial growth factor can signal through platelet-derived growth factor receptors. J Cell Biol 2007;177:489-500.
69. Veevers-Lowe J, Ball SG, Shuttleworth A et al. Mesenchymal stem cell migration is regulated by fibronectin through a5b1-integrinmediated activation of PDGFR-b and potentiation of growth factor signals. J Cell Sci 2011; 124:1288-1300.
70. He J, Baum LG. Galectin interactions with extracellular matrix and effects on cellular function. Methods Enzymol 2006;417: 247-256.
71. Chan J, O'Donoghue K, Gavina M et al. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. STEM CELLS 2006;24:1879-1891.
72. Kishore R, Qin G, Luedemann C et al. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest 2005;115:1785-1796.
73. Eckle T, Brodsky K, Bonney M et al. HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium. PLoS Biol 2013;11:e1001665.
74. Zheng G, Huang L, Tong H et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: A randomized, placebocontrolled pilot study. Respir Res 2014;15: 39.
75. François M, Copland IB, Yuan S et al. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-g licensing. Cytotherapy 2012;14: 147-152.